Clinical trial · Interventional
Electronic Patient Reported Outcomes in Patients With Gastrointestinal Cancers
Electronic Patient Reported Outcomes in Patients With Gastrointestinal Cancers at Risk for Unplanned ED Visits and Hospitalizations
NCT05359042CI-TRIAL-00076915withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Logistical constraints
Summary
Brief summary (as posted)
This is a randomized trial of patients with gastrointestinal (GI) cancers treated at University of California, San Francisco (UCSF) who are starting a new line of systemic therapy to evaluate the feasibility of electronic patient reported outcome (ePRO) platform.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Cancer Metastatic | Digestive System Neoplasm | PROBABILISTIC | 0.70 |
| Gastrointestinal Cancers | Malignant Digestive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Electronic Patient Reported Outcomes platform | Other | — | UNRESOLVED |
| Health Related Quality of Life Surveys | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- ePRO Assessment Tool
- description
- Participants will receive either a text message or an email inviting them to engage in the health chat. Participant assessments including HRQOL and user experience will be administered via the platform. Participants will also be able to participate in short, interactive patient education modules related to the infusion and side effect management.
- interventionNames
- Other: Electronic Patient Reported Outcomes platform
- Other: Health Related Quality of Life Surveys
- type
- NO_INTERVENTION
- label
- Standard of Care
- description
- Participants in the standard of care arm will report symptoms via standard of care messaging through UCSF MyChart or telephone calls throughout the study period, and complete standard of care HRQoL surveys.
Primary outcomes (2)
- measure
- Proportion of patients who engaged with the ePRO tool
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years and older * Diagnosis of gastrointestinal cancers: esophageal, gastric, hepatocellular carcinoma, cholangiocarcinoma, pancreatic, neuroendocrine, small intestine, colorectal and anal cancers. * Patients can have early stage or advanced cancer and will be starting treatment with new, standard of care infusion therapy regimen at UCSF. * Ability to understand study procedures and to comply with them for the entire length of the study. * No limit on prior lines of therapy. * Access to smartphone, tablet, or computer with capability to use symptom tracking web site (must have mobile phone number or email address). * Willing and able to provide written, signed informed consent in English. * Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it. Exclusion Criteria: * Patients who have already started therapy prior to study enrollment. * Patients who are receiving their treatment outside of UCSF. * Participation in another clinical trial (therapeutic or non-therapeutic). * Patients who are on therapy with oral oncolytics or combination therapy of oral oncolytics and infusional agents. * Patients who are non-English speakers.
References
Publications (0)
Data not yet available
No reference posted for this study.